Table 1.
Patient characteristics at baseline
| mRNA boost | Vector boost | |
|---|---|---|
| n | 24 | 22 |
| Age | 63.4 ± 11.4 | 61.2 ± 14.9 |
| Sex: female | 10 (41.7) | 7 (31.8) |
| Diagnosis (%) | ||
| AIH | 1 (4.2) | 0 (0.0) |
| CTD | 1 (4.2) | 1 (4.5) |
| HTX | 8 (33.3) | 10 (45.5) |
| HTX + multiple myeloma | 1 (4.2) | 0 (0.0) |
| LiTX | 2 (8.3) | 3 (13.6) |
| LiTX + KTX | 1 (4.2) | 0 (0.0) |
| LuTX | 5 (20.8) | 6 (27.3) |
| Breast cancer | 1 (4.2) | 0 (0.0) |
| MS | 2 (8.3) | 0 (0.0) |
| Multiple myeloma | 1 (4.2) | 1 (4.5) |
| Pemphigus vulgaris | 1 (4.2) | 0 (0.0) |
| RCC | 0 (0.0) | 1 (4.5) |
| Weeks between 2nd vaccination and screening | 15.2 ± 3.0 | 13.9 ± 4.2 |
| Detectable peripheral B-cells (%) | 23 (95.8) | 21 (95.5) |
| Tacrolimus (%) | 13 (54.2) | 16 (72.7) |
| Mycophenolate (%) | 17 (70.8) | 13 (59.1) |
| Everolimus (%) | 2 (8.3) | 2 (9.1) |
| Sirolimus (%) | 2 (8.3) | 1 (4.5) |
| Ciclosporin (%) | 2 (8.3) | 2 (9.1) |
| Daratumumab (%) | 2 (8.3) | 0 (0.0) |
| IMiDs (%) | 1 (4.2) | 1 (4.5) |
| JAKi (%) | 1 (4.2) | 0 (0.0) |
| Hydroxychloroquine (%) | 1 (4.2) | 0 (0.0) |
| Fingolimod (%) | 2 (8.3) | 0 (0.0) |
| Vinorelbin (%) | 1 (4.2) | 0 (0.0) |
| Cabozantinib (%) | 0 (0.0) | 1 (4.5) |
| Prednisone (%) | 8 (33.3) | 9 (40.9) |
| Number of concomitant immunosuppressants (%) | ||
| 1 | 6 (25.0) | 5 (22.7) |
| 2 | 8 (33.3) | 11 (50.0) |
| 3 | 10 (41.7) | 6 (27.3) |
| Primary vaccination (%) | ||
| BNT162b2 | 20 (83.3) | 21 (95.5) |
| mRNA-1273 | 4 (16.7) | 1 (4.5) |
Data are presented as n (%) or mean ± standard deviation (SD).
AIH autoimmune hepatitis, CTD connective tissue disease, HTX heart transplant, LiTX liver transplant, KTX kidney transplant, LuTX lung transplant, MS multiple sclerosis, RCC renal cell carcinoma, IMiDs immunomodulatory imide drug, JAKi Janus kinase inhibitor.